Replimune (REPL) 8-K Biologics license application (BLA) submission intended for 2H 2024; first patient expected to be enrolled in IGNYTE-3 confirmatory trial in Q3 2024

Exhibit 99.2

IGNYTE Investor Event (6/6/24) 1 Primary Analysis of the IGNYTE Registrational Cohort in Anti-PD1 Failed Melanoma June 6, 2024

IGNYTE Investor Event (6/6/24) 2 Safe Harbor Any statements contained herein that are not statements of historical facts may be deemed to be forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements regarding the advancement, timing and sufficiency of our clinical trials, patient enrollments in our existing and planned clinical trials and the timing thereof, the results of our clinical trials, the timing and release of our clinical data, statements regarding our expectations about our cash runway, our goals to develop and commercialize our product candidates, our expectations regarding the size of the patient populations for our product candidates if approved for commercial use and other statements identified by words such as “could,” “expects,” “intends,” “may,” “plans,” “potential,” “should,” “will,” “would,” or similar expressions and the negatives of those terms. Forward-looking statements are not promises or guarantees of future performance, and are subject to a variety of risks and uncertainties, many of which are beyond our control, and which could cause actual results to differ materially from those contemplated in such forward-looking statements. These factors include risks related to our limited operating history, our ability to generate positive clinical trial results for our product candidates, the costs and timing of operating our in-house manufacturing facility, the timing and scope of regulatory approvals, changes in laws and regulations to which we are subject, competitive pressures, our ability to identify additional product candidates, political and global macro factors including the impact of global pandemics and related public health issues, the ongoing military conflicts between Russia-Ukraine and Israel-Hamas and the impact on the global economy and related governmental imposed sanctions, and other risks as may be detailed from time to time in our Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q, and other reports we file with the Securities and Exchange Commission. Our actual results could differ materially from the results described in or implied by such forward-looking statements. Forward-looking statements speak only as of the date hereof, and, except as required by law, we undertake no obligation to update or revise these forward-looking statements.

IGNYTE Investor Event (6/6/24) 3 Today’s Speakers/Q&A Panel CAROLINE ROBERT Professor Head of Dermatology Unit, Institute Gustave Roussy and Co-Director Melanoma Research Unit INSERM, Paris-Sud University. MICHAEL WONG Professor Melanoma Medical Oncology, University of Texas MD Anderson Cancer Center SUSHIL PATEL CEO Replimune KOSTAS XYNOS Chief Medical Officer Replimune ROBERT COFFIN Founder and Chief Scientist Replimune

IGNYTE Investor Event (6/6/24) 4 Today’s Agenda • Data Summary • ASCO 2024 Recap: IGNYTE 12-month Investigator-assessed Data • Topline IGNYTE Primary Analysis by Independent Central Review • Progress to BLA • Q&A

IGNYTE Investor Event (6/6/24) 5 Data Summary • Strong primary analysis data: ORR of 33.6% (mRECIST 1.1) and 32.9% (RECIST 1.1) by independent central review • Improvement versus investigator-assessed ORR of 32.1% (mRECIST 1.1) • Median DOR >35 months; 100% of responses last >6 months (from baseline) • DOR by independent central review consistent with investigator assessment • Phase 3 confirmatory study (IGNYTE-3) with first patient expected to be enrolled in Q3 2024; BLA submission planned for 2H 2024 *N=140

IGNYTE Investor Event (6/6/24) 6 ASCO Recap: Anti-PD1 Failed Melanoma Patients from the IGNYTE Clinical Trial

IGNYTE Investor Event (6/6/24) 7 Options are Limited in Melanoma Following Progression on Anti-PD1 Therapy • Further single agent anti-PD1 for patients having confirmed PD on prior anti-PD1 gives a response rate of 6-7%1,2 • Nivolumab + ipilimumab is a potential option3, but toxicity is high4-5 • Anti-LAG3 plus anti–PD1 has not demonstrated meaningful efficacy in the anti–PD1 failed setting6 • For BRAF mutant tumors, BRAF-targeted therapy responses are generally transient7 • T-VEC + pembrolizumab has limited activity outside of the adjuvant setting, with no responses seen in patients with visceral disease8-9 • TIL therapy for select patients gives response rates of ~30%, but comes with toxicity (nearly all patients have grade 4 toxicity)10 CTLA-4, cytotoxic T-lymphocyte an6gen 4; LAG3, lymphocyte-ac6va6on gene 3; PD-1, programmed cell death protein 1; TIL, tumor infiltra6ng lymphocyte 1. Mooradian MJ, et al. Oncology. 2019;33(4):141-8. 2. Beaver JA, et al. Lancet Oncol. 2018;19(2):229-39. 3. Na6onal Comprehensive Cancer Network. NCCN Clinical Prac6ce Guidelines in Oncology (NCCN Guidelines®). Melanoma: Cutaneous. Version 2.2024. 4. Pires da Silva I, et al. Lancet Oncol. 2021;22(6):836-47. 5. VanderWalde AM, et al. Presented at the American Associa6on of Cancer Research Annual Mee6ng 2022. New Orleans. 6. Ascierto PA, et al. J Clin Oncol. 2023;41(15)2724-35. 7. Dixon-Douglas JR, et al. Curr Oncol Rep. 2022;24(8):1071-9. 8. Gastman B, et al. J Clin Oncol. 2022;40(16_suppl):9518. 9. Hu-Lieskovan S, et al. Cancer Res. 2023;83(7_suppl):3275. 10. US Food and Drug Administra6on. BLA clinical review and evalua6on - AMTAGVI. BLA 125773. Updated February 6, 2024. Accessed May 31, 2024].hcps://www.fda.gov/media/176951/download.

IGNYTE Investor Event (6/6/24) 8 IGNYTE Study Design Anti-PD1 Failed Melanoma Cohort Key eligibility criteria Confirmed progression while on prior anti-PD1 therapyc At least 8 weeks of prior anti–PD1, confirmed progression while on anti– PD1; anti–PD1 must be the last therapy before clinical trial. Patients on prior adjuvant therapy must have progressed while on prior adjuvant treatment. Primary objectives • Safety and tolerability • Efficacy as assessed by ORR using modified RECIST 1.1 criteria Secondary objective DOR, CR rate, DCR, PFS, by central & investigator review, ORR by investigator review, and 1-year and 2-year OS Anti–PD1 failed melanoma cohort (140 pts; 16 pts treated in prior cohorts: Total=156) Screening RP1 RP1+nivolumaba Nivolumab 28 days 2 weeks Cycle 1 Cycles 2–8 Cycle 9 Cycles 10–30b 2 weeks 2 weeks Nivolumab 28 days 2 weeks 2 weeks 2 weeks aDosing with nivolumab begins at dose 2 of RP1 (C2D15). bOp?on to reini?ate RP1 for 8 cycles if criteria are met. c. Non-neurological solid tumors CR, complete response; CT, computed tomography; DCR, disease control rate; DOR, dura?on of response; ECOG, Eastern Coopera?ve Oncology Group; LD, longest diameter; ORR, objec?ve response rate; OS, overall survival; PD-1, programmed cell death protein 1; PFS, progression-free survival; pfu, plaque-forming unit; Q4W, every 4 weeks; RECIST, Response Evalua?on Criteria in Solid Tumors. Primary analysis to be conducted when all patients have ≥ 12 months follow up

IGNYTE Investor Event (6/6/24) 9 Baseline Clinical Characteristics A ‘real world’ anti-PD1 failed melanoma population was enrolled • Good representation of each of the sub-groups of patients who progress on prior anti-PD1 therapy Median follow up is 15.4 months (range 0.5-55.5) Patients, n (%) All patients (N = 156) Age (median [range]) Sex Female 62 (21-91) 52 (33.3) Male 104 (66.7) Stage IIIb/IIIc/IVM1a 75 (48.1) IVM1b/c/d 81 (51.9) Prior therapy Anti–PD1 only as adjuvant therapy 39 (25.0) Anti–PD1 not as adjuvant therapy 117 (75.0) Anti–PD1 & anti–CTLA-4 74 (47.4) Received BRAF-directed therapy 17 (10.9) Patients, n (%) All patients (N = 156) Other disease characteristics Primary resistance to prior anti–PD1a 105 (67.3) Secondary resistance to prior anti–PD1b,c 51 (32.7) BRAF wt 103 (66.0) BRAF mutant 53 (34.0) LDH ≤ULN 105 (67.3) LDH >ULN 50 (32.1) LDH unknown 1 (0.6) Data cutoff: March 8th 2024. aPrimary resistance: Progressed within 6 months of star6ng the immediate prior course of an6–PD-1 therapy; bSecondary resistance: Progressed ager 6 months of treatment on the immediate prior course of an6-PD-1 therapy; c Includes 2 pt unknown resistance status. CTLA-4, cytotoxic T-lymphocyte an6gen 4; LDH, lactate dehydrogenase; PD-1, programmed cell death protein 1; ULN, upper limit of normal; wt, wild-type.

IGNYTE Investor Event (6/6/24) 10 Efficacy Investigator assessed data with all patients having at least 12 months follow up Data cutoff: March 8th 2024. BOR, best overall response; CR, complete response; CTLA-4, cytotoxic T-lymphocyte an6gen 4; PD-1, programmed cell death protein 1; PD, progressive disease; PR, par6al response; ORR, objec6ve response rate; SD, stable disease. • 1 in 3 patients achieved an objective response (32.7%) • Consistent ORR across subgroups, including: o 27% ORR in patients who had prior anti–PD1 & anti–CTLA-4 o 34% ORR in patients who are primary resistant to their prior anti-PD1 therapy All patients enrolled in IGNYTE BOR n (%) All patients (n = 156) Prior single-agent anti–PD1 (n = 82) Prior anti– PD1/CTLA-4 (n = 74)a Stage IIIb-IVM1a (n = 75) Stage IVM1b-d (n = 81) 1o resistance to anti–PD1 (n = 105) 2o resistance to anti–PD1 (n = 51)b CR 23 (14.7) 18 (22.0) 5 (6.8) 18 (24.0) 5 (6.2) 18 (17.1) 5 (9.8) PR 28 (17.9) 13 (15.9) 15 (20.3) 13 (17.3) 15 (18.5) 18 (17.1) 10 (19.6) SD 34 (21.8) 18 (22.0) 16 (21.6) 19 (25.3) 15 (18.5) 17 (16.2) 17 (33.3) PD 63 (40.4) 31 (37.8) 32 (43.2) 24 (32.0) 39 (48.1) 47 (44.8) 16 (31.4) ORR 51 (32.7c) 31 (37.8) 20 (27.0) 31 (41.3) 20 (24.7) 36 (34.3) 15 (29.4) aEight pa)ents were treated with sequen)al an)-CTLA-4 and an)-PD1 (ORR for prior combined an)-CTLA-4/an)-PD1 was 25.8%). bIncludes one pa)ent with unknown resistance status. cORR for the 140-pa)ent registra)on intended cohort was 32.1%

IGNYTE Investor Event (6/6/24) 11 Depth of Response • Target lesions were reduced in >50% of patients • Responses were seen across disease stages, including CRs in patients with stage IVM1b/c disease Patients Data cutoff: March 8th 2024. The target lesion response is shown for pa6ents with at least one post-baseline assessment. CR, complete response; PD, progressive disease; PR, par6al response; SD, stable disease. Best overall response Best overall response Best overall response Best overall response PDo PD ++ SDSD □ PRPR PR△ CR CR

IGNYTE Investor Event (6/6/24) 12 • 70.4% of responding patients had non-injected lesions • Injected and non-injected lesions responded with similar duration and kinetics • Depth of response independent of injection status Responses in non-injected lesions demonstrate systemic benefit Responses are Systemic Change in size of individual injected and non-injected lesions Includes both target and non-target lesions for RECIST assessment, measured from CT/MRI scans for radiologically assessable lesions (responders from the first 75 pa6ents enrolled into the registra6on intended cohort). 58/75 pa6ents had at ≥ 1 non-injected lesion, of whom 15 achieved a response based on those lesions only (excludes possible response in injected lesions); ORR of 25.9% on the basis of non-injected lesions only. First presented at ASCO 2023. First 28 responders from the study • All lesions were measured, not only target lesions • Each line represents an individual lesion RP1 Injected RP1 Non-injected

IGNYTE Investor Event (6/6/24) 13 Duration of Response From baseline • Responses are durable, with a median DOR of 36.6 months Probability (%) >6 months >12 months >18 months >24 months 100% 84.2% 74.9% 65.2% Data cutoff: March 8th 2024. Dura6on of response defined as 6me from baseline to end of response for responders. DOR, dura6on of response. # at risk The median follow up for responders is 27.9 months (range 10.5-55.5)

IGNYTE Investor Event (6/6/24) 14 Safety: Treatment-related AEs (N = 156) RP1 combined with nivolumab continues to be a generally well tolerated regimen • Predominantly grade 1 and 2 constitutional-type side effects • Low incidence of grade 3 and 4 events • No grade 5 events Additional grade 3 and 4 events <5% Grade 3: Two each of rash maculo-papular and hypophysitis; 1 each of tumor pain, infusion-related reaction, muscular weakness, abdominal pain, amylase increased, dermatitis bullous, eczema, immune-mediated enterocolitis, immune-mediated hepatitis, paresthesia, acute left ventricular failure, arthritis, cancer pain, enterocolitis, extranodal marginal zone B-cell lymphoma (MALT type), hyponatremia, injection site necrosis, left ventricular dysfunction, memory impairment, meningitis aseptic, edema, palmar-plantar erythrodysesthesia syndrome, peripheral sensory neuropathy, radiculitis brachial, sinus arrhythmia, tricuspid valve incompetence, and type 1 diabetes mellitus Grade 4: One each of lipase increased, alanine aminotransferase increased, blood bilirubin increased, cytokine release syndrome, myocarditis, and hepatic cytolysis, splenic rupture Data cutoff: March 8th 2024. MALT, mucosa-associated lymphoid tissue; TRAE, treatment-related adverse event. Preferred term, n (%) TRAEs occurring in >5% of patients Grade 1–2 Grade 3 Grade 4 Grade 5 Total (N = 156) Chills 53 (34.0) 1 (0.7) 0 0 53 (34.0) Fatigue 51 (32.7) 2 (1.3) 0 0 52 (33.3) Pyrexia 49 (31.4) 0 0 0 49 (31.4) Nausea 35 (22.4) 0 0 0 35 (22.4) Influenza-like illness 30 (19.2) 0 0 0 30 (19.2) Injection-site pain 23 (14.7) 0 0 0 23 (14.7) Diarrhea 21 (13.5) 1 (0.6) 0 0 21 (13.5) Vomiting 21 (13.5) 0 0 0 21 (13.5) Headache 20 (12.8) 0 0 0 20 (12.8) Pruritus 20 (12.8) 0 0 0 20 (12.8) Asthenia 13 (8.3) 1 (0.6) 0 0 14 (9.0) Arthralgia 11 (7.1) 1 (0.7) 0 0 11 (7.1) Myalgia 11 (7.1) 0 0 0 11 (7.1) Decreased appetite 9 (5.8) 1 (0.6) 0 0 10 (6.4) Rash 9 (5.8) 1 (0.6) 0 0 10 (6.4)

IGNYTE Investor Event (6/6/24) 15 Conclusions • RP1 combined with nivolumab in melanoma patients who had confirmed progression on prior anti-PD1 continues to show: • Deep and durable, systemic responses • A favorable safety profile, with generally ‘on target’ and transient grade 1–2 side effects indicative of systemic immune activation • 1 in 3 patients experienced a response (ORR: 32.7%) • 27% ORR in patients had prior anti–PD1/anti–CTLA-4 • 34% ORR in patients who had primary resistance to their immediate prior anti-PD1 therapy • Clinically meaningful activity was seen across all enrolled subgroups • 55% of patients experienced clinical benefit (CR + PR + SD) • Responses were highly durable • All patients followed for at least 12 months • All responses lasted at least 6 months, with median DOR >36 months

IGNYTE Investor Event (6/6/24) 16 Topline Data for the IGNYTE Registrational Cohort in Anti-PD1 Failed Melanoma Assessed by Independent Central Review

IGNYTE Investor Event (6/6/24) 17 Strong IGNYTE Primary Analysis Data by Independent Central Review Overall Response Rate (registration-intended cohort: n=140) (%) Investigator Assessment Independent Central Review1 Modified* RECIST 1.1 32.1% Primary Endpoint Modified* RECIST 1.1 33.6% RECIST 1.1** 32.9% * Confirmation of PD requires further tumor increase from the first observation of PD; responses can be captured at any time up until next anti-cancer therapy2 ** Requested by FDA, with confirmation of PD required; responses not included in ORR after the first confirmed PD All patients with at least 12 months follow up Data cutoff: March 8th 2024. Median follow up for the 140 pa?ents in the registra?on intended cohort is 15.8 months (range 0.5-47.6); 1Each central reviewer selects their own target lesions without knowledge of RP1 injec?on status. 2This was to allow for the poten?al for prolonged pseudo-progression (>1 scan interval) before response; however, in prac?ce the pseudo-progression seen was transient (generally <1 scan interval)

IGNYTE Investor Event (6/6/24) 18 Patient Example Prior atezolizumab+cobimetinib, ipilimumab, SX682 (CXCR-inhibitor)+ atezolizumab, ipilimumab+nivolumab Baseline 9 Months Baseline 9 Months Responses in uninjected distant and visceral tumors including healing of lytic bone lesions (increasing sclerosis & new internal bone formation seen) RP1 injected Non-injected

IGNYTE Investor Event (6/6/24) 19 Patient Example Prior pembrolizumab (1L), encorafenib+binimetinib (2L), and nivolumab+relatlimab (3L) Baseline 4 months 15 months

IGNYTE Investor Event (6/6/24) 20 IGNYTE Data Shows Clinically Meaningful Benefit • One third of patients respond (ORR: 33.6%) • Responses are durable • 100% last >6 months, median DOR >35 months (from baseline) • RP1 combined with nivolumab continues to be a generally well tolerated regimen • Predominantly grade 1/2 constitutional-type side effects • Low incidence of grade 3 and 4 events; no grade 5 events • Full data to be submitted for presentation at an upcoming medical congress

IGNYTE Investor Event (6/6/24) 21 Progress to BLA

IGNYTE Investor Event (6/6/24) 22 IGNYTE Data and Phase 3 Confirmatory Trial Incorporates FDA Feedback Type B meeting in 2021 A real-world population, representative of the IO progressed landscape should be enrolled Patients should have confirmed progression while on anti-PD1 therapy, with minimum 8 weeks exposure Responses should be durable Clinically meaningful activity should be seen across all melanoma sub-groups enrolled Responses should be demonstrably systemic, i.e. of both injected and uninjected lesions Type C meeting in Sept 2023 FDA acknowledged that the IGNYTE population represents one of unmet need Contribution of components demonstrated by reference to the literature* Centrally reviewed data by RECIST 1.1 and mRECIST 1.1 All patients followed for at least 12 months (protocol primary analysis timepoint) All responding patients followed for at least 6 months from response initiation Phase 3 confirmatory study will be underway by BLA submission *The response rate for further single agent anti-PD1 for patients having confirmed PD on prior anti-PD1 is expected to be 6-7%; Ribas et al Lancet Oncology 2018 (19), Hodi et al JCO 2016 (34)

IGNYTE Investor Event (6/6/24) 23 Advanced cutaneous melanoma Progressed on anti-PD1 AND anti-CTLA-4 OR not candidates for anti-CTLA-4 Up to 2 prior lines of systemic therapy for advanced disease BRAF mutant patients must have been treated with BRAF/MEK-directed therapy1 N=~400 Randomized 1:1 3-year follow-up post last patient enrolled IGNYTE-3: Confirmatory Phase 3 Trial Design* 1 For BRAF mutant patients prior BRAF/MEK-directed therapy is required unless deemed not clinically indicated at investigator’s discretion due to documented concurrent medical condition or prior toxicity; *ClinicalTrials.gov ID: NCT6264180 RP1 and Nivolumab in Ipi-Nivo Pretreated Patients RP1 + Nivolumab Treatment of Physician’s Choice (TPC) - Nivolumab-Relatlimab (Opdualag) - Chemotherapy (DTIC, TMZ, paclitaxel/nab-paclitaxel) - Rechallenge with anti-PD1 monotherapy (nivolumab or pembrolizumab) Primary Endpoint Overall Survival Key Secondary Endpoints Progression Free Survival and Objective Response Rate

IGNYTE Investor Event (6/6/24) 24 Manufacturing on Track to Support RP1 BLA and Commercialization • Type C meeting with FDA confirmed alignment on Chemistry, Manufacturing and Controls (CMC) plans to support RP1 BLA submission • 63,000 square foot state-of-the-art facility for GMP manufacturing in Framingham, MA • RP1 BLA consistency lot runs complete • Commercial inventory build underway • Scale expected to be sufficient to cover global commercialization of RP1 and RP2 • Commercially attractive cost of goods & ‘off the shelf’ product practicality Commercial scale in-house manufacturing established

IGNYTE Investor Event (6/6/24) 25 U.S. Melanoma RP1 Patient Opportunity Compelling potential option for a broad range of anti-PD1 failed patients ~13K patients1 Addresses a high unmet need in anti-PD1 failed settings 1L prior adjuvant 2L+ BRAF WT 2L+ BRAF MT An#-PD1 failed melanoma Source: 1Melanoma US treated patient population for 2030 based on CancerMPact® Patient Metrics, Cerner Enviza (available from www.cancermpact.com Accessed 15 Oct 2023), with adjustments to future 2L+ treatment rates based on primary market research. RP1+nivolumab is well positioned to be the first option for patients who progress on a PD1-based regimen (in adjuvant or 1L setting), given: 1. Deep & durable responses 2. Safety profile 3. Ease of administration

IGNYTE Investor Event (6/6/24) 26 RP1 Well Positioned for BLA Submission and Commercialization • Strong IGNYTE primary endpoint ORR data by independent central review of 33.6% (mRECIST 1.1) • Durable responses: 100% last >6 months, median DOR >35 months (from baseline) • Manufacturing on track to support RP1 BLA & global commercialization • Type C meeting with FDA confirmed alignment on CMC plans • First patient expected to be enrolled in the phase 3 confirmatory study (IGNYTE-3) in Q3 2024, with BLA submission planned for 2H 2024 • Attractive commercial RP1 opportunity in anti-PD1 failed melanoma • Significant patient population and unmet need • Compelling risk:benefit profile

IGNYTE Investor Event (6/6/24) 27 Thank You